Equity Strategy
After a 12% NIFTY run-up, where do we trim?
Mid-cap valuations have stretched well past their 10-year median P/E. We walk through three positions we're scaling back, the screen we used, and what we're rotating into.
Weekly notes from our research desk on Indian equities, debt, unlisted, and global flows. No tip sheets, no forecasts dressed up as facts.
Mid-cap valuations have stretched well past their 10-year median P/E. We walk through three positions we're scaling back, the screen we used, and what we're rotating into.
Across a 20-year SIP at ₹25,000/month, the difference between a regular and direct plan adds up to ₹38L. We model it scheme-by-scheme.
NSE India and Tata Capital have firm pricing; Pharmeasy and Oyo are still in price discovery. Our quarterly cap-table refresh, with implied valuations.
With the RBI on a holding pattern and inflation easing toward target, longer-dated G-Secs are starting to look attractive. The math, the risks, and the alternatives.
Buying ELSS in March is the worst time of year. Buying in May is among the best. We unpack why, and which schemes survived our quality screen.
A real portfolio review of one of our investors who hit pause on rebalancing during the 2023–24 run, and outperformed by 3.4% p.a. as a result.
FII flows, INR-USD, and the import-cost translation — three transmission channels and the asset classes most exposed.
We re-ran the math at 2026 premium tables. The conclusion is unchanged: pure term plus mutual fund SIP beats whole-life by a wide margin.
Embassy and Mindspace yields have recovered to 7%+, but rental escalations are slowing. We rate the four listed REITs on yield, growth, and balance-sheet strength.